SGLT-2抑制剂抗高血压作用及研究进展

Antihypertensive Effects of SGLT-2 Inhibitors and Progress in Research

钠–葡萄糖协同转运蛋白2抑制剂(sodium-glucose transporter 2 inhibitors, SGLT-2i)是一类较新颖的降糖药物,不依赖于刺激胰岛素分泌,通过尿糖来降低血糖,大量的证据表明其在心血管领域具有突出应用价值。高血压患病人群基数庞大,高血压不单是众多疾病的合并症,同时也是许多疾病的危险因素并影响相关预后。随着对SGLT-2i的深入了解及受试者临床试验的结果总结,降压作用受到关注,突显了该药物单纯降糖之外的潜在价值及多效性。现就SGLT-2i临床应用中的降压证据及可能的降压机制进行综述。

Sodium-glucose transporter 2 inhibitors (SGLT-2i) are a relatively new class of hypoglycemic agents that do not rely on stimulation of insulin secretion to lower blood glucose via urinary glucose, and a large body of evidence suggests that they have outstanding cardiovascular applications. With a large population base, hypertension is not only a comorbidity of many diseases, but also a risk fac-tor for many diseases and affects the prognosis. With the deeper understanding of SGLT-2i and the summary of results from clinical trials in subjects, the antihypertensive effect has come under scru-tiny, highlighting the potential value and multiplicity of the drug beyond glucose lowering alone. The evidence for antihypertensive effects and possible antihypertensive mechanisms in the clinical application of SGLT-2i are reviewed.